Viking Therapeutics (NASDAQ: VKTX) Just Broke Out and Could Rise 18%–35% From Here

Viking Therapeutics, Inc. (NASDAQ: VKTX) just broke out of a multi-month symmetrical triangle on heavy volume and looks headed even higher.

As we’ll get to just ahead, the combination of breakthrough Phase 2 oral VK2735 data showing up to 12.2% weight loss, fully enrolled pivotal Phase 3 obesity trials and a top-tier CMO hire positioning Viking as a premier M&A target in the GLP-1 space, and a fresh technical breakout makes VKTX one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders — with its lead candidate, VK2735, a dual GLP-1/GIP receptor agonist for obesity that is being advanced in both an injectable (subcutaneous) formulation and a convenient oral pill formulation.

In plain English, when Big Pharma giants like Eli Lilly and Novo Nordisk look at the next generation of obesity drugs to keep up with surging global demand for GLP-1 weight-loss therapies, Viking’s VK2735 program sits near the top of the list. Its business hinges on the efficacy and safety data emerging from its massive Phase 3 subcutaneous trials (VANQUISH-1 and VANQUISH-2), the late-stage progression of its differentiated oral formulation, and the very real possibility of an M&A buyout from a larger player desperate to buy its way into the category.

VKTX’s latest move reflects a powerful confluence of developments — clinical, strategic, and structural — that have come together in rapid succession to fundamentally reframe the company’s near-term growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and VKTX is looking less like a binary clinical-stage biotech waiting on the next data drop and more like an advanced, well-funded obesity franchise with clear differentiation across injectable, oral, and maintenance dosing — sitting at the intersection of clinical execution, sector tailwinds, and M&A optionality.

The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Symmetrical Triangle Pattern Breakout: VKTX has broken out of a symmetrical triangle on the daily chart — the converging trendlines of lower highs and higher lows that mark a tightening standoff between buyers and sellers. That coiling action compresses volatility, and compression resolves with a directional thrust. The breakout candle closed on a clear volume expansion (6.22M), and volume is the confirmation that separates a real breakout from a fakeout. The consolidation is over, and the resolution is to the upside.

VKTX – Daily Chart

#2 Price above MAs: At its June 23 close of $34.81, price finished above the 50-day SMA ($31.46) and the 200-day SMA ($32.48), with the two averages clustered roughly a dollar apart. Tightly bunched MAs reflect a market that has worked through its overhead supply and lost its directional bias — exactly the setup that precedes an expansion move. Now that price has cleared both, that $31.50–$32.50 band flips from overhead resistance into a defined support shelf buyers can lean on if the breakout retests.

#3 MACD Above Signal Line: On the daily, the MACD line sits above its signal line, with the histogram positive and widening. The expanding histogram is the key tell: it shows the spread between the two lines accelerating, not just holding — short-term momentum is pulling away from the longer-term baseline. That’s a momentum thrust building underneath the price breakout, not a stale crossover drifting near the zero line.

#4 Bullish ADX: The +DI (34.58) sits well above the –DI (14.12), a wide spread that puts buyers firmly in control of direction. The ADX itself (18.91) is still below the 20 threshold that confirms a strong trend — but it has turned up from below and is climbing toward that line. Read together, this is the signature of a trend in its early innings: directional conviction is already there, and trend strength is just beginning to ramp. That’s arguably more attractive than a high ADX, which often marks a trend already mature.

#5 Above Support Area: On the weekly, price has lifted off a former resistance level that now acts as support — the pink dotted line near $28.85. Price is also holding above both the 50-week SMA ($32.60) and the 200-week SMA ($31.21), with those averages now stacked beneath price. The higher-timeframe structure confirms bulls retain control, and the $28.85 shelf gives the entire thesis a clean line in the sand.

VKTX – Weekly Chart

#6 Stochastic Crossover From Oversold: The weekly %K crossed above %D out of oversold territory — the highest-conviction signal this oscillator produces, because a cross near the lower bound means selling pressure has been fully exhausted and fresh buyers are stepping in at depressed levels. That cross has since resolved into a powerful upswing, with %K now at 79.44 and pressing the 80 band. The momentum thrust is confirmed; just note the easy oversold-bounce portion of the move is largely behind, and follow-through now depends on price, not the oscillator.

#7 RSI Reclaiming Bullish Territory: The weekly RSI sits at 55.14, above both the 50 equilibrium line and its own signal (48.46), and it’s rising. The 50 level is the dividing line between net buying and net selling pressure; clearing it matters, but the slope matters more — a rising RSI distinguishes a genuine momentum build from a listless drift above the midline. This profile is characteristic of an early-to-mid-stage uptrend, where momentum is still accumulating rather than peaking. Paired with the stochastic thrust, the weekly timeframe now fully backs the daily breakout thesis.

Risks to Consider

Even strong setups can fail, especially in a high-beta clinical-stage biotech like Viking Therapeutics. A few things could knock the stock off course:

• A breakdown back below the symmetrical triangle breakout level on heavy volume
• Negative company-specific news, broader market weakness, or a sector-wide rerating that pressures GLP-1 and obesity-linked names
• Binary clinical risk — the entire valuation is effectively tied to VK2735, meaning any safety signals, adverse events, or delays in the VANQUISH-1 and VANQUISH-2 Phase 3 trials would weigh heavily on the stock
• Cash burn — Q1 2026 net loss was roughly $158.3 million, and Phase 3 obesity trials require large patient populations and long follow-up; if trials are extended, Viking may need to raise additional capital and dilute shareholders
• Pre-commercial profile — there is no product revenue today, so the stock remains driven entirely by clinical outcomes and sentiment rather than financial fundamentals
• Competition — Eli Lilly (Zepbound), Novo Nordisk (Wegovy), Pfizer, Structure Therapeutics, and others are advancing competing orals, injectables, and combination therapies that could pressure Viking’s positioning even if VK2735 succeeds
• Valuation sensitivity — at roughly $4 billion in market cap for a clinical-stage name, the stock is highly sensitive to data misses, macro biotech sentiment swings, or any reset in the GLP-1 enthusiasm cycle
• Execution and timeline risk on the Q4 2026 Oral VK2735 Phase 3 initiation and the broader pipeline progression

The Bottom Line

VKTX is breaking out of a multi-month symmetrical triangle on the daily chart while lifting cleanly off a resistance-turned-support shelf on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: Phase 2 oral data showing up to 12.2% mean weight loss, a fully enrolled pivotal Phase 3 program and ~$603 million in cash, and a premier M&A target profile in the white-hot GLP-1 space.

Combine that with multiple clinical and commercial catalysts staggered through the next 18 months — Q2 earnings, the Q3 maintenance dosing readout, the Q4 oral Phase 3 initiation, and continued M&A speculation — and VKTX looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our exact entry level, both price targets that imply 18%–35% potential upside, and the stop-loss we’re using to manage the downside.

Recommended Trade Setup

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $3.80 per share, the target rewards are about $6.50 and $12.50 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If VKTX drops to or below the $31.70 stop-loss before the $35.50 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.

Happy Trading!
Tara and Greg